A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction

Naomi Fischer, Elad Moisseiev, Michael Waisbourd, Michaella Goldstein, Anat Loewenstein Department of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Purpose: The study reported here investigated the rates of systemic serious adverse events...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fischer N, Moisseiev E, Waisbourd M, Goldstein M, Loewenstein A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/9011acd3bb744c8a90fd4a430571cad7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9011acd3bb744c8a90fd4a430571cad7
record_format	dspace
spelling	oai:doaj.org-article:9011acd3bb744c8a90fd4a430571cad72021-12-02T02:19:30ZA matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction1177-54671177-5483https://doaj.org/article/9011acd3bb744c8a90fd4a430571cad72013-03-01T00:00:00Zhttp://www.dovepress.com/a-matched-control-comparison-of-serious-adverse-events-after-intravitr-a12575https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Naomi Fischer, Elad Moisseiev, Michael Waisbourd, Michaella Goldstein, Anat Loewenstein Department of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Purpose: The study reported here investigated the rates of systemic serious adverse events (SAEs) following treatment with intravitreal bevacizumab for age-related macular degeneration (AMD) in comparison with a matched control group. Methods: A retrospective age- and sex-matched case-control design was used. Data were collected using patient charts and telephone surveys. The main outcome measure was difference in number of hospital admissions between the two groups. Hospitalizations were further analyzed according to whether or not they were due to arteriothrombotic SAEs. Results: Each group comprised 65 participants. There were significantly more hospital admissions among bevacizumab-treated patients than in the control group (P = 0.039). Sub-analysis of hospitalizations due to arteriothrombotic causes did not reveal a statistically significant difference between groups (P = 0.629). Conclusion: The results suggest that intravitreal bevacizumab is not associated with an increased risk of arteriothrombotic SAEs. Its widespread use for the treatment of AMD appears to be systemically safe. Keywords: Avastin®, serious adverse events, safetyFischer NMoisseiev EWaisbourd MGoldstein MLoewenstein ADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 621-625 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Fischer N Moisseiev E Waisbourd M Goldstein M Loewenstein A A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
description	Naomi Fischer, Elad Moisseiev, Michael Waisbourd, Michaella Goldstein, Anat Loewenstein Department of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Purpose: The study reported here investigated the rates of systemic serious adverse events (SAEs) following treatment with intravitreal bevacizumab for age-related macular degeneration (AMD) in comparison with a matched control group. Methods: A retrospective age- and sex-matched case-control design was used. Data were collected using patient charts and telephone surveys. The main outcome measure was difference in number of hospital admissions between the two groups. Hospitalizations were further analyzed according to whether or not they were due to arteriothrombotic SAEs. Results: Each group comprised 65 participants. There were significantly more hospital admissions among bevacizumab-treated patients than in the control group (P = 0.039). Sub-analysis of hospitalizations due to arteriothrombotic causes did not reveal a statistically significant difference between groups (P = 0.629). Conclusion: The results suggest that intravitreal bevacizumab is not associated with an increased risk of arteriothrombotic SAEs. Its widespread use for the treatment of AMD appears to be systemically safe. Keywords: Avastin®, serious adverse events, safety
format	article
author	Fischer N Moisseiev E Waisbourd M Goldstein M Loewenstein A
author_facet	Fischer N Moisseiev E Waisbourd M Goldstein M Loewenstein A
author_sort	Fischer N
title	A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
title_short	A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
title_full	A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
title_fullStr	A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
title_full_unstemmed	A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
title_sort	matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/9011acd3bb744c8a90fd4a430571cad7
work_keys_str_mv	AT fischern amatchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT moisseieve amatchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT waisbourdm amatchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT goldsteinm amatchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT loewensteina amatchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT fischern matchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT moisseieve matchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT waisbourdm matchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT goldsteinm matchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction AT loewensteina matchedcontrolcomparisonofseriousadverseeventsafterintravitrealinjectionsofbevacizumabforagerelatedmaculardegenerationandcataractextraction
_version_	1718402540880527360

A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction

Ejemplares similares